Nonnucleoside reverse transcriptase (NNRT) inhibitors {R82913; (+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazo [4,5,1-jkl[1,41-benzodiazepin- NNRT inhibitors, Cl-TIBO induced a single mutation (Y181 to C) in reverse transcriptase (RT) that accounted for the resistance. BI-RG-587 induced a different mutation (V1O6--A) in AZT resistance backgrounds. A series ofviable HIV-1 variants was constructed by site-directed mutagenesis of the RT, which harbored multiple drug resistance mutations, including Y181 to C. HIV-1 that was coresistant to NNRT inhibitors and 2',3'-dideoxyinosine resulted when a 2',3'-dideoxyinosine resistance mutation (L74 to V) was also present in RT. By contrast, however, the Y181 to C mutation in an AZT resistance background signcantly suppresed resistance to AZT, while it conferred resistance to NNRT inhibitors. However, the V106-)A substitution did not cause suppression of preexisting AZT resistance. Since certain combinations of nucleoside analogs and NNRT inhibitors might result in the development of coresistance, careful analysis of clinical isolates obtained during combination therapy will be needed to determine the potential significance of these observations.
Recent efforts in the search for new drugs that can be used to treat human immunodeficiency virus (HIV) disease have resulted in the identification of several families of nonnucleoside inhibitors active specifically against HIV type 1 (HIV-1) (1, 9, 21, 23, 27) . Although these are diverse in structure (e.g., derivatives of benzodiazepines [TIBO compounds], dipyridodiazepinones, pyridinones, and piperazines), they all seem to share a common mechanism of action, mediated through selective binding to HIV-1 reverse transcriptase (RT) (1, 4, 5, 7, 9, 13, 21, 31, 32) . Biochemical -and genetic studies have demonstrated that amino acid residues Y181 and Y188 are critical for the anti-HIV-1 activities of these compounds (4, 6, 29) . Furthermore, recently published X-ray structural data confirm that one of these inhibitors, BI-RG-587 (nevirapine), binds in a pocket which includes these residues (12) . This is close to the putative polymerase catalytic site of RT but is probably distinct from the nucleotide binding region (12) . Surprisingly, nonnucleoside RT (NNRT)-resistant variants are rapidly selected in cell culture in the presence of these compounds, and there appears to be significant cross-resistance between each class of inhibitor (22, 26) . Consistent with these observations, genetic analysis of resistant HIV-1 variants selected with BI-RG-587 or pyridinone derivatives revealed a common mutation in RT (Y181 to C), although a second substitution at codon 103 was also observed with a pyridinone-resistant virus (22, 26) . These data also confirmied-the importance of Y181 in RT for NNRT inhibitor ' binding. - 
-
Prolonged clinical use of HIV inhibitors such as zidovudine (3'-azido-3'-deoxythymidine; AZT) has led to the ident1incatiTn and caliFacterization of drug-resistant HIV strains (3,'t6' 30) .'Decreases in AZT susceptibility are caused by a set of five specific amino acid substitutions in RT, at codons 41, 67, 70, 215, and 219 (11, 18) . These mutations seem to occur in an ordered manner, resulting in a stepwise increase in resistance as substitutions accumulate (2, 11) . Introduction of the five substitutions by mutagenesis into a wild-type virus background, singly and in various combinations, has confirmed that each contributes to AZT resistance (11, 17, 18 (11, 17, 18) . These AZT-resistant strains are cross-resistant only to nucleoside analogs containing a 3'-azido group, not to other nucleoside analogs such as 2',3'-dideoxyinosine (ddl) or the new group of nonnucleoside RT inhibitors (1, 9, 14, 25) .
In an attempt to combat AZT resistance, one strategy has been to switch individuals from AZT therapy to ddI therapy. Unfortunately, this sometimes results in ddl-susceptible virus becoming less susceptible to the drug (30) . In some instances, however, virus that was initially AZT resistant appears to regain susceptibility to AZT during ddI therapy (30) . A novel mutation in RT (L74 to V) accounts for the increased resistance to ddl and, remarkably, is able to "silence" or suppress the effects of AZT resistance mutations (30) MATERIALS AND METHODS Cells and virus. The human T-lymphoblastoid cell line MT-2 (10) was used to propagate HIV-1 for in vitro selection of resistant virus and for electroporation experiments. MT-2 cells were maintained in RPMI 1640 medium containing 10% (vol/vol) fetal calf serum plus antibiotics. Polybrene (2 ,ug/ml) was included for HIV-1 growth and drug resistance selection. HT4LacZ-1 cells (human CD4+ HeLa cells) (24) were used in cell inhibitor susceptibility assays (14) . These cells were maintained in Dulbecco modified Eagle medium containing 10% (vol/vol) fetal calf serum plus antibiotics.
The HIV-1 strains used in this study were the wild-type virus HXB2 derived from the infectious molecular clone pHXB2-D (8) and a number of previously described variants constructed from pHXB2-D by site-directed mutagenesis of specific nucleotides in RT (11, 17, 18, 30) . HIV-1 stocks were stored as cell-free culture supernatants at -70°C.
Selection of NNRT inhibitor-resistant HIV-1 in MT-2 cells.
MT-2 cells (2 x 106) were infected with cell-free HIV-1 at low multiplicity (less than 0.1 50% tissue culture infective dose per cell) and were exposed to inhibitor initially at subinhibitory concentrations as described previously for the selection of AZT-resistant strains (15) . The virus passaged in these experiments was wild-type HXB2 or the highly AZTresistant variant HIVRTMC (mutations in RT were as follows: Asp-67 to Asn, Lys-70 to Arg, Thr-215 to Phe, Lys-219
to Gln). The NNRT inhibitor (+)-S-4,5,6,7-tetrahydro-9-
4]-benzodiazepin-2(1H)-thione (R82913; Cl-TIBO) was purchased from Pharmatech International. The concentration of Cl-TIBO added to the culture medium during each passage for HXB2 and HIVRTMC is indicated in Table 1 . The concentration used at each passage was empirically derived to allow maximum replication of each virus in the presence of inhibitor. The concentration of BI-RG-587 used in selection experiments is indicated in the legend to Table 2 .
Assessment of susceptibility to inhibitors by plaque reduction assay. The susceptibility of HIV-1 to inhibitors was determined by plaque reduction (foci of multinucleated giant cells) formed in monolayers of HT4LacZ-1 cells as described previously (14) . Appropriate dilutions of cell-free virus from MT-2 cell cultures were used to infect HT4LacZ-1 cell monolayers in 24-well plates (inhibitor-free virus control wells contained about 100 to 150 plaques). When virus supernatants from in vitro resistance selection experiments was used for susceptibility analysis, the inoculum was removed after a 1-h adsorption period (at 37°C) prior to the addition of fresh culture medium containing various amounts of inhibitor. This was to eliminate carryover of inhibitor from MT-2 cell cultures. Susceptibility tests were performed between one and four times for each virus. Variations in IC50s in duplicate assays were minimal (generally less than twofold). Nucleotide sequence analysis of RT. DNA was extracted from HIV-infected MT-2 cells, and the complete 1.7-kb RT-coding region of Cl-TIBO-passaged HXB2 was amplified by polymerase chain reaction (PCR) as described previously (18) . RT was ligated with the M13 vector mptacl8.1 to enable expression of active enzyme in Escherichia coli.
Clones expressing active RT were sequenced by the dideoxynucleotide chain termination method (28) . The complete nucleotide sequences of five RT clones were determined from HXB2 virus passaged in Cl-TIBO by using a set of specific oligonucleotide primers (18) . The viruses selected with BI-RG-587 and HIVRTMC selected with Cl-TIBO were analyzed by direct sequencing of PCR products as described previously (31a) . Fragments of RT were generated using the oligonucleotide primers A and NE1, as detailed elsewhere (17) .
Construction of RT mutants. Mutations were created in the RT-coding region by site-directed mutagenesis with synthetic oligonucleotides as described previously (19) . A number of different HIV-1 RT constructs in the vector mptacl8.1 (expressing active enzyme) were used as initial targets for mutagenesis. These included wild-type RT derived from pHXB2-D and previously constructed mutants containing AZT or ddI resistance mutations (11, 17, 18, 30) .
Preparation and assay of RT. Crude extracts of recombinant RT were prepared by infecting E. coli TG-1 at a high multiplicity with M13 bacteriophage clones. After induction with isopropyl-13-D-thiogalactopyranoside, cells were lysed and RT was obtained by fractionation with a high salt concentration as described previously (20) . RT activity was routinely assayed by using poly(rA) oligo(dT) as the primer-template and [3H]TTP (5 ,uM and 10 pCi/ml, respectively); in inhibition studies with Cl-TIBO, however, poly (rC) oligo(dG) and [3H]dGTP (2 ,uM and 22 pCi/ml, respectively) were used. The poly(rC) oligo(dG) primer-template was used for inhibition studies because this has been shown to be a more sensitive assay system for measurement of HIV-1 inhibition by Cl-TIBO (23) .
Construction of HIV-1 variants by recombination. The RT-coding region obtained from M13 clones was transferred into the HXB2 genetic background by homologous recombination with the RT-deleted proviral clone pHIVARTB stEII as described previously (11, 30) . RT variants created by site-directed mutagenesis (as outlined above) were produced as replicative-form M13 DNA, digested with EcoRI and HindIII to release the 1.7-kb RT fragment, and mixed with pHIVARTBstEII linearized with BstEII. This DNA mixture was used to transfect MT-2 cells by electroporation as described previously (19) . Cells were maintained in RPMI 1640 medium containing 10% (vol/vol) fetal calf serum plus antibiotics, and virus stocks were prepared from cell-free supernatants at about 14 days posttransfection.
Detection of Tyr-181 to Cys mutation by selective PCR. Selective PCR was used to discriminate wild-type virus (Tyr-181) from mutant virus (Cys-181) at RT codon 181 in samples of DNA from virus-infected MT-2 cells. DNA was extracted and selective PCR was performed as described previously for AZT resistance mutations (17) . The selective oligonucleotide primers 181W (5'-CAAATCATCCATGTA TTGTT-3') and 181M (5'-CAAATCATCCATGTATTGTC-3'), with variations at the 3' positions, were used in PCR assays. They were paired with the common primer A (5'-TTCCCATTAGTCCTATT-3'). PCR conditions were identical to those described previously for detection of the AZT resistance mutations at codon 215 (3, 17) . DNA products were analyzed by electrophoresis in 1.5% agarose-Trisborate-EDTA gels. The size of the specific PCR band was 563 bp.
RESULTS
Selection of HIV-1 variants resistant to Cl-TIBO. The wild-type HIV-1 strain HXB2 and the AZT-resistant mutant HIVRTMC were passaged separately in MT-2 cells in the presence of increasing Cl-TIBO concentrations (Table 1) . Cell-free virus recovered after each passage was assessed for its susceptibility to Cl-TIBO and AZT. By the fifth passage, viruses derived from HXB2 and HIVRTMC were substantially resistant to Ci-TIBO, with IC50s being >50-fold those for the parental viruses (Table 1) . During passage in Cl-TIBO, HXB2 remained fully susceptible to AZT; however, the initially AZT-resistant variant HIVRTMC appeared to become considerably less resistant to this inhibitor ( Table 1) . Selection of HIV-1 variants resistant to BI-RG-587. Passage of wild-type HIV-1 in BI-RG-587 causes rapid selection of resistant virus (25) . To investigate the possibility of coresistance between AZT and BI-RG-587, we passaged the AZTresistant mutants HIVRTMC and HXB41V215Y (RT mutations, Met-l->Leu and Thr-215-)Tyr) in MT-2 cells with BI-RG-587. By passage 3, the resulting viruses were both resistant to BI-RG-587, with IC50s about 100-fold higher than those of parental viruses (Table 2) . It is interesting to note that both BI-RG-587-resistant isolates retained their original resistance to AZT ( generate such virus variants, the RT mutants described above were mixed with the RT-deleted HXB2 molecular clone pHIVARTBstEII and were used to transfect MT-2 cells. Viable virus is created when recombination occurs between the clones to produce full-length infectious DNA with an intact RT-coding region. Infectious virus from transfections with all of the mutant RT clones was recovered. These variants all replicated in MT-2 cells to similar titers, and the presence of the expected mutations in each was confirmed by selective PCR (data not shown). Plaque reduction assays were performed with HIV-1 mutants in monolayers of the cell line HT4LacZ-1. Variants with combinations of mutations conferring resistance to NNRT inhibitors (Y181 to C) and to ddI (L74 to V) were first analyzed. The results of this analysis are given in Table 4 . As expected, all variants with Y181 to C in RT were resistant to Cl-TIBO (IC50s increased 25-to 40-fold) and cross-resistant to BI-RG-587 (IC50s increased 60-to 210-fold compared with IC50s for parental strains). All variants were equally susceptible to AZT; however, those with both the Y181 to C and L74 to V mutations in their RTs were coresistant to NNRT inhibitors and ddI. Variants with combinations of mutations conferring resistance to NNRT inhibitors (Y181 to C) and AZT (M41 to L, T215 to Y and D67 to N, K70 to R, 7215 to F, K219 to Q) were then analyzed. Again, the results of this analysis (Table  5) showed that those variants with the Y181 to C mutation in any genetic background were resistant to Cl-TIBO (IC50s increased 18-to 25-fold) and cross-resistant to BI-RG-587 (IC50s increased 112-to 200-fold compared with IC50s for parental strains). As expected, all of these mutants were equally susceptible to ddM. Remarkably however, preexisting AZT-resistant strains showed a decrease in AZT resistance when the Y181 to C change was present. Previous studies (22, 26) have shown that the Y181 to C RT mutation in a wild-type HIV-1 background is sufficient alone to confer resistance to NNRT inhibitors. In the present study, it was confirmed that exposure of wild-type HIV-1 to Cl-TIBO in cell culture also causes rapid selection of the same mutation at codon 181. The presence of this mutation in a variety of different genetic backgrounds did not cause significant detrimental effects on RT activity. Furthermore, when incorporated into a replication-competent HIV-1 clone, virus mutants harboring these multiple drug resistance mutations were viable in cell culture. The presence of the Y181 to C mutation in the context of AZT resistance or ddI resistance mutations always conferred both Cl-TIBO and BI-RG-587 resistance. This implies that these nucleoside analog resistance mutations have little influence on the codon 181 substitution. However, positive interactions can occur between amino acid substitutions in RT to boost the level of NNRT inhibitor resistance, as has been observed with pyridinone resistance in which codon 103 and 181 changes can occur together (22) .
The importance of these in vitro studies needs to be (20a) . In this case, the codon 181 mutation also present in this virus population may be dominant, since suppression of AZT resistance clearly occurred. Clinical trials conducted to determine the value of combining AZT with an NNRT inhibitor will be of considerable interest. In individuals who have already received prolonged AZT monotherapy and harbor AZT-resistant strains, careful assessment of HIV susceptibility before and after the addition of an NNRT inhibitor should be performed to determine whether it is able to potentiate AZT sensitivity (via induction of the codon 181 change) and render the resulting virus susceptible again to AZT. It will also be interesting to observe the pattern of resistance in HIV isolates from individuals given combinations of AZT and an NNRT inhibitor without initially receiving AZT alone.
Further studies to determine the phenotypic resistance proffles of HIV-1 variants constructed with other combinations of drug resistance mutations should prove valuable. It might be the case that certain combinations render the RT sufficiently less active to impair the replication capacity of the virus. While the use of specific drug combinations might result in resistance to one inhibitor, perhaps investigators will discover combinations that will simultaneously force the virus to remain (or become) susceptible to a second drug. The potential clinical benefit of this situation would then await evaluation. 
